HIV vaccine development at Duke University Medical Center

Immunol Res. 2000;22(2-3):263-9. doi: 10.1385/ir:22:2-3:263.

Abstract

With the AIDS epidemic continuing to spread throughout the world, development of a safe, practical, and effective HIV vaccine is a national priority. HIV vaccine research efforts are currently targeted towards design of HIV immunogens that induce both cellular and humoral immunity. This brief review summarizes ongoing work at the Duke University School of Medicine on HIV vaccine development.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines*
  • Academic Medical Centers*
  • Adjuvants, Immunologic
  • Amino Acid Sequence
  • Animals
  • Clinical Trials as Topic
  • Cytokines / immunology
  • Epitopes / genetics
  • HIV Envelope Protein gp120 / genetics
  • HIV Infections / prevention & control*
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • HLA Antigens / immunology
  • Humans
  • Molecular Sequence Data
  • North Carolina
  • Peptide Fragments / genetics
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccines, Synthetic / immunology

Substances

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Cytokines
  • Epitopes
  • HIV Envelope Protein gp120
  • HIV envelope protein gp120 (305-321)
  • HLA Antigens
  • Peptide Fragments
  • Vaccines, Synthetic